LONDON (Alliance News) - Pharmaceutical services company Clinigen Group PLC on Wednesday said its Idis Managed Access arm and Horizon Pharma PLC have started a managed access programme in Europe for Horizon's Ravicti Oral Liquid.
Ravicti has centralised marketing approval from the European Medicines Agency for the treatment of urea cycle disorders in children and adults which cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
The managed access programme will make Ravicti available to patients with urea cycle disorders in selected European countries prior to the commercial launch of the product.
Shares in Clinigen were up 4.0% to 575.00 pence Wednesday. Dublin-based Horizon Pharma is quoted on NASDAQ in New York.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
